Sign In
Buy WVE
$5.76
+0.0700 (+1.23%)
At Close: Jun 03, 2026
Is This Weight Loss Drug Stock a Buy on the Dip?
04:45pm, Wednesday, 01'st Apr 2026
Wave Life Sciences' shares dropped after its weight loss candidate failed to impress in a phase 1 study. However, this product could actually be successful if it can confirm its recent phase 1 results
First Look: Stocks Jump on Iran Hopes; Oracle Cuts; OpenAI Raises
07:37am, Wednesday, 01'st Apr 2026
Stock News Wall Street rallies on Iran de-escalation hopes: Major U.S. indexes posted their best day since May, led by Big Tech as Nvidia (NVDA) rose over 5%, w
Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?
04:21am, Wednesday, 01'st Apr 2026
Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price in
WAVE Life Sciences (NASDAQ:WVE) Hits New 12-Month Low – What’s Next?
04:54am, Saturday, 28'th Mar 2026
WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) hit a new 52-week low on Thursday. The company traded as low as $5.11 and last traded at $5.2590, with a volume of 11044062 shares traded. The s
Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity Transcript
04:15pm, Friday, 27'th Mar 2026
Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity Transcript
WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks
12:25pm, Friday, 27'th Mar 2026
Wave Life Sciences stock plunges after interim phase I data for WVE-007 showed modest fat reduction at higher dose, despite some sustained benefits.
Wave Life Sciences Slips as Obesity Data Fails to Convince
10:00am, Friday, 27'th Mar 2026
Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets following updated Phase 1 INLIGHT trial data for WVE-007, the company's obesit
Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints
05:30pm, Thursday, 26'th Mar 2026
Expand NASDAQ: WVE Wave Life Sciences Today's Change (-49.84%) $-6.13 Current Price $6.17 Key Data Points Market Cap $2.3B Day's Range $5.04 - $6.48 52wk Range $5.04 - $21.73 Volume 1.5M Avg Vol 3.3M
Wave Life Sciences shares plummet on weight loss therapy update
12:34pm, Thursday, 26'th Mar 2026
Wave Life Sciences (NASDAQ:WVE) saw its shares fall more than 52% following the release of six-month Phase 1 data for WVE-007, its investigational INHBE GalNAc-siRNA therapy, despite results showing i
Why Is Wave Life Sciences Stock Falling After Weight Loss Study Data?
11:25am, Thursday, 26'th Mar 2026
At the six-month follow-up, a single 240 mg dose of WVE-007 demonstrated significant placebo-adjusted reductions in visceral fat by 14%, total fat by 5%, and waist circumference by 3%, while stabilizi
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Wave Life Sciences Ltd. (NASDAQ: WVE). The investigation focuses on Wave
Wave Life Sciences shares plunge as data for high dose of obesity drug disappoints
09:33am, Thursday, 26'th Mar 2026
Wave Life Sciences shares plunged over 55% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a dangerous type of belly fat.
Wave Life Sciences shares plummet on weight loss therapy update
08:30am, Thursday, 26'th Mar 2026
Wave Life Sciences (NASDAQ:WVE) saw its shares fall more than 52% following the release of six-month Phase 1 data for WVE-007, its investigational INHBE...
At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of “Moderate Buy” by Brokerages
02:51am, Friday, 13'th Mar 2026
Shares of WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) have received an average rating of "Moderate Buy" from the fourteen brokerages that are covering the stock, Marketbeat Ratings reports
